231 related articles for article (PubMed ID: 19631529)
1. Imidazo-pyrazine derivatives as potent CXCR3 antagonists.
Du X; Gustin DJ; Chen X; Duquette J; McGee LR; Wang Z; Ebsworth K; Henne K; Lemon B; Ma J; Miao S; Sabalan E; Sullivan TJ; Tonn G; Collins TL; Medina JC
Bioorg Med Chem Lett; 2009 Sep; 19(17):5200-4. PubMed ID: 19631529
[TBL] [Abstract][Full Text] [Related]
2. Optimization of a series of quinazolinone-derived antagonists of CXCR3.
Liu J; Fu Z; Li AR; Johnson M; Zhu L; Marcus A; Danao J; Sullivan T; Tonn G; Collins T; Medina J
Bioorg Med Chem Lett; 2009 Sep; 19(17):5114-8. PubMed ID: 19632842
[TBL] [Abstract][Full Text] [Related]
3. Design and optimization of imidazole derivatives as potent CXCR3 antagonists.
Du X; Chen X; Mihalic JT; Deignan J; Duquette J; Li AR; Lemon B; Ma J; Miao S; Ebsworth K; Sullivan TJ; Tonn G; Collins TL; Medina JC
Bioorg Med Chem Lett; 2008 Jan; 18(2):608-13. PubMed ID: 18063364
[TBL] [Abstract][Full Text] [Related]
4. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
[TBL] [Abstract][Full Text] [Related]
5. Novel CXCR3 antagonists with a piperazinyl-piperidine core.
McGuinness BF; Carroll CD; Zawacki LG; Dong G; Yang C; Hobbs DW; Jacob-Samuel B; Hall JW; Jenh CH; Kozlowski JA; Anilkumar GN; Rosenblum SB
Bioorg Med Chem Lett; 2009 Sep; 19(17):5205-8. PubMed ID: 19647429
[TBL] [Abstract][Full Text] [Related]
6. Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
Thoma G; Baenteli R; Lewis I; Wagner T; Oberer L; Blum W; Glickman F; Streiff MB; Zerwes HG
Bioorg Med Chem Lett; 2009 Nov; 19(21):6185-8. PubMed ID: 19783143
[TBL] [Abstract][Full Text] [Related]
7. [SCA 40 and derivatives: new bronchodilators in an imidazo(1,2-a)pyrazine series].
Bonnet PA; Vitse O; Bénezech V; Subra G; Fabréguettes JR; Zanik L; Laurent F; Michel A; Bompart J; Chapat JP
Ann Pharm Fr; 1998; 56(4):155-9. PubMed ID: 9770008
[TBL] [Abstract][Full Text] [Related]
8. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.
Li AR; Johnson MG; Liu J; Chen X; Du X; Mihalic JT; Deignan J; Gustin DJ; Duquette J; Fu Z; Zhu L; Marcus AP; Bergeron P; McGee LR; Danao J; Lemon B; Carabeo T; Sullivan T; Ma J; Tang L; Tonn G; Collins TL; Medina JC
Bioorg Med Chem Lett; 2008 Jan; 18(2):688-93. PubMed ID: 18061451
[TBL] [Abstract][Full Text] [Related]
11. Research on heterocyclic compounds. X.-Imidazo[1,2-a]pyrazine derivatives: synthesis and antiinflammatory activity.
Abignente E; Arena F; De Caprariis P; Nuzzetti R; Marmo E; Lampa E; Rosatti E; Ottavo R
Farmaco Sci; 1981 Jan; 36(1):61-80. PubMed ID: 6970683
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
da Silva YK; Augusto CV; de Castro Barbosa ML; de Albuquerque Melo GM; de Queiroz AC; de Lima Matos Freire Dias T; Júnior WB; Barreiro EJ; Lima LM; Alexandre-Moreira MS
Bioorg Med Chem; 2010 Jul; 18(14):5007-15. PubMed ID: 20598893
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB
J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
[TBL] [Abstract][Full Text] [Related]
15. Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3325-8. PubMed ID: 23602400
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.
Mukaiyama H; Nishimura T; Kobayashi S; Ozawa T; Kamada N; Komatsu Y; Kikuchi S; Oonota H; Kusama H
Bioorg Med Chem; 2007 Jan; 15(2):868-85. PubMed ID: 17095233
[TBL] [Abstract][Full Text] [Related]
17. Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.
Watson RJ; Allen DR; Birch HL; Chapman GA; Hannah DR; Knight RL; Meissner JW; Owen DA; Thomas EJ
Bioorg Med Chem Lett; 2007 Dec; 17(24):6806-10. PubMed ID: 17964154
[TBL] [Abstract][Full Text] [Related]
18. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
19. Palladium-catalyzed direct heck arylation of dual pi-deficient/pi-excessive heteroaromatics. Synthesis of C-5 arylated imidazo[1,5-a]pyrazines.
Wang JX; McCubbin JA; Jin M; Laufer RS; Mao Y; Crew AP; Mulvihill MJ; Snieckus V
Org Lett; 2008 Jul; 10(14):2923-6. PubMed ID: 18576663
[TBL] [Abstract][Full Text] [Related]
20. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.
Mader M; de Dios A; Shih C; Bonjouklian R; Li T; White W; López de Uralde B; Sánchez-Martinez C; del Prado M; Jaramillo C; de Diego E; Martín Cabrejas LM; Dominguez C; Montero C; Shepherd T; Dally R; Toth JE; Chatterjee A; Pleite S; Blanco-Urgoiti J; Perez L; Barberis M; Lorite MJ; Jambrina E; Nevill CR; Lee PA; Schultz RC; Wolos JA; Li LC; Campbell RM; Anderson BD
Bioorg Med Chem Lett; 2008 Jan; 18(1):179-83. PubMed ID: 18039577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
